Characterization of the Endometrial MSC Marker Ectonucleoside Triphosphate Diphosphohydrolase-2 (NTPDase2/CD39L1) in Low- and High-Grade Endometrial Carcinomas: Loss of Stromal Expression in the Invasive Phenotypes
Abstract
:1. Introduction
2. Materials and Methods
2.1. Samples
2.2. Antibodies
2.3. Immunolabeling Experiments
2.4. In Situ ATPase Activity Experiments
2.5. In Silico TCGA (The Cancer Genome Atlas) and Survival Analysis
2.6. Statistical Analysis of Ectonucleotide Triphosphate Diphosphohydrolase-2 (NTPDase2) Presence
3. Results
3.1. Expression of NTPDase2 in Tumor and Stromal Cells in Endometrial Carcinomas (ECs)
3.1.1. Redistribution of NTPDase2 Expression with the Tumor Grade: From Containment to the Cilia to the Whole Tumor Cell
3.1.2. NTPDase2 Expression in the Stromal Component of Tumor: Changes during Tumor Progression
3.1.3. NTPDase2+/SUSD2+ (Sushi Domain Containing 2) Perivascular Cell Population: Endometrial Mesenchymal Stem Cells (eMSCs) Are also Present in ECs
3.1.4. Coexistence of Adenomyosis and Endometrial Polyps with ECs: Comparison of NTPDase2 Expression in Tumor and Non-Tumor Tissues
3.1.5. Overall-Survival Probability and Progression-Free Survival: Patients with High Levels of NTPDase2 Show a Better Prognosis for EC
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Gargett, C.E.; Schwab, K.E.; Deane, J.A. Endometrial stem/progenitor cells: The first 10 years. Hum. Reprod. Update 2016, 22, 137–163. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tempest, N.; Maclean, A.; Hapangama, D.K. Endometrial Stem Cell Markers: Current Concepts and Unresolved Questions. Int. J. Mol. Sci. 2018, 19, 3240. [Google Scholar] [CrossRef] [Green Version]
- Chan, R.W.; Schwab, K.E.; Gargett, C.E. Clonogenicity of human endometrial epithelial and stromal cells. Biol. Reprod. 2004, 70, 1738–1750. [Google Scholar] [CrossRef]
- de Miguel-Gómez, L.; López-Martínez, S.; Francés-Herrero, E.; Rodríguez-Eguren, A.; Pellicer, A.; Cervelló, I. Stem Cells and the Endometrium: From the Discovery of Adult Stem Cells to Pre-Clinical Models. Cells 2021, 10, 595. [Google Scholar] [CrossRef]
- Yegutkin, G.G. Enzymes involved in metabolism of extracellular nucleotides and nucleosides: Functional implications and measurement of activities. Crit. Rev. Biochem. Mol. Biol. 2014, 49, 473–497. [Google Scholar] [CrossRef] [PubMed]
- Burnstock, G. Short- and long-term (trophic) purinergic signalling. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2016, 371, 20150422. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Trapero, C.; Vidal, A.; Rodriguez-Martinez, A.; Sevigny, J.; Ponce, J.; Coroleu, B.; Matias-Guiu, X.; Martin-Satue, M. The ectonucleoside triphosphate diphosphohydrolase-2 (NTPDase2) in human endometrium: A novel marker of basal stroma and mesenchymal stem cells. Purinergic Signal. 2019, 15, 225–236. [Google Scholar] [CrossRef]
- Trapero, C.; Vidal, A.; Fernandez-Montoli, M.E.; Coroleu, B.; Tresserra, F.; Barri, P.; Gomez de Aranda, I.; Sevigny, J.; Ponce, J.; Matias-Guiu, X.; et al. Impaired Expression of Ectonucleotidases in Ectopic and Eutopic Endometrial Tissue Is in Favor of ATP Accumulation in the Tissue Microenvironment in Endometriosis. Int. J. Mol. Sci. 2019, 20, 5532. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Masuda, H.; Anwar, S.S.; Bühring, H.J.; Rao, J.R.; Gargett, C.E. A novel marker of human endometrial mesenchymal stem-like cells. Cell Transplant. 2012, 21, 2201–2214. [Google Scholar] [CrossRef]
- Scarfi, S. Purinergic receptors and nucleotide processing ectoenzymes: Their roles in regulating mesenchymal stem cell functions. World J. Stem Cells 2014, 6, 153–162. [Google Scholar] [CrossRef] [Green Version]
- Roszek, K.; Wujak, M. How to influence the mesenchymal stem cells fate? Emerging role of ectoenzymes metabolizing nucleotides. J. Cell Physiol. 2018, 234, 320–334. [Google Scholar] [CrossRef] [Green Version]
- Zippel, N.; Limbach, C.A.; Ratajski, N.; Urban, C.; Luparello, C.; Pansky, A.; Kassack, M.U.; Tobiasch, E. Purinergic receptors influence the differentiation of human mesenchymal stem cells. Stem Cells Dev. 2012, 21, 884–900. [Google Scholar] [CrossRef] [PubMed]
- Coppi, E.; Pugliese, A.M.; Urbani, S.; Melani, A.; Cerbai, E.; Mazzanti, B.; Bosi, A.; Saccardi, R.; Pedata, F. ATP modulates cell proliferation and elicits two different electrophysiological responses in human mesenchymal stem cells. Stem Cells 2007, 25, 1840–1849. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ferrari, D.; Gulinelli, S.; Salvestrini, V.; Lucchetti, G.; Zini, R.; Manfredini, R.; Caione, L.; Piacibello, W.; Ciciarello, M.; Rossi, L.; et al. Purinergic stimulation of human mesenchymal stem cells potentiates their chemotactic response to CXCL12 and increases the homing capacity and production of proinflammatory cytokines. Exp. Hematol. 2011, 39, 360–374.e5. [Google Scholar] [CrossRef] [PubMed]
- Ferlay, J.; Soerjomataram, I.; Dikshit, R.; Eser, S.; Mathers, C.; Rebelo, M.; Parkin, D.M.; Forman, D.; Bray, F. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 2015, 136, E359–E386. [Google Scholar] [CrossRef] [PubMed]
- Matias-Guiu, X.; Prat, J. Molecular pathology of endometrial carcinoma. Histopathology 2013, 62, 111–123. [Google Scholar] [CrossRef]
- Soslow, R.A.; Tornos, C.; Park, K.J.; Malpica, A.; Matias-Guiu, X.; Oliva, E.; Parkash, V.; Carlson, J.; McCluggage, W.G.; Gilks, C.B. Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists. Int. J. Gynecol. Pathol. 2019, 38 (Suppl. 1), S64–S74. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bergamin, L.S.; Braganhol, E.; Zanin, R.F.; Edelweiss, M.I.; Battastini, A.M. Ectonucleotidases in tumor cells and tumor-associated immune cells: An overview. J. Biomed. Biotechnol. 2012, 2012, 959848. [Google Scholar] [CrossRef] [Green Version]
- Pellegatti, P.; Raffaghello, L.; Bianchi, G.; Piccardi, F.; Pistoia, V.; Di Virgilio, F. Increased level of extracellular ATP at tumor sites: In vivo imaging with plasma membrane luciferase. PLoS ONE 2008, 3, e2599. [Google Scholar] [CrossRef] [PubMed]
- de Andrade Mello, P.; Coutinho-Silva, R.; Savio, L.E.B. Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives. Front. Immunol. 2017, 8, 1526. [Google Scholar] [CrossRef] [Green Version]
- North, R.A. Molecular physiology of P2X receptors. Physiol. Rev. 2002, 82, 1013–1067. [Google Scholar] [CrossRef]
- Wang, Q.; Wang, L.; Feng, Y.H.; Li, X.; Zeng, R.; Gorodeski, G.I. P2X7 receptor-mediated apoptosis of human cervical epithelial cells. Am. J. Physiol. Cell Physiol. 2004, 287, C1349–C1358. [Google Scholar] [CrossRef] [Green Version]
- Li, X.; Zhou, L.; Feng, Y.H.; Abdul-Karim, F.W.; Gorodeski, G.I. The P2X7 receptor: A novel biomarker of uterine epithelial cancers. Cancer Epidemiol. Biomark. Prev. 2006, 15, 1906–1913. [Google Scholar] [CrossRef] [Green Version]
- Li, X.; Qi, X.; Zhou, L.; Catera, D.; Rote, N.S.; Potashkin, J.; Abdul-Karim, F.W.; Gorodeski, G.I. Decreased expression of P2X7 in endometrial epithelial pre-cancerous and cancer cells. Gynecol. Oncol. 2007, 106, 233–243. [Google Scholar] [CrossRef] [Green Version]
- Colas, E.; Perez, C.; Cabrera, S.; Pedrola, N.; Monge, M.; Castellvi, J.; Eyzaguirre, F.; Gregorio, J.; Ruiz, A.; Llaurado, M.; et al. Molecular markers of endometrial carcinoma detected in uterine aspirates. Int. J. Cancer 2011, 129, 2435–2444. [Google Scholar] [CrossRef]
- Aliagas, E.; Vidal, A.; Texido, L.; Ponce, J.; Condom, E.; Martin-Satue, M. High expression of ecto-nucleotidases CD39 and CD73 in human endometrial tumors. Mediat. Inflamm. 2014, 2014, 509027. [Google Scholar] [CrossRef] [Green Version]
- Bowser, J.L.; Blackburn, M.R.; Shipley, G.L.; Molina, J.G.; Dunner, K., Jr.; Broaddus, R.R. Loss of CD73-mediated actin polymerization promotes endometrial tumor progression. J. Clin. Investig. 2016, 126, 220–238. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aliagas, E.; Vidal, A.; Torrejon-Escribano, B.; Taco Mdel, R.; Ponce, J.; de Aranda, I.G.; Sevigny, J.; Condom, E.; Martin-Satue, M. Ecto-nucleotidases distribution in human cyclic and postmenopausic endometrium. Purinergic Signal. 2013, 9, 227–237. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wachstein, M.; Meisel, E.; Niedzwiedz, A. Histochemical demonstration of mitochondrial adenosine triphosphatase with the lead-adenosine triphosphate technique. J. Histochem. Cytochem. 1960, 8, 387–388. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Villamonte, M.L.; Torrejon-Escribano, B.; Rodriguez-Martinez, A.; Trapero, C.; Vidal, A.; Gomez de Aranda, I.; Sevigny, J.; Matias-Guiu, X.; Martin-Satue, M. Characterization of ecto-nucleotidases in human oviducts with an improved approach simultaneously identifying protein expression and in situ enzyme activity. Histochem. Cell Biol. 2018, 149, 269–276. [Google Scholar] [CrossRef]
- Gorodeski, G.I. Purinergic Signalling in the Reproductive System. Auton. Neurosci. 2015, 191, 82–101. [Google Scholar] [CrossRef] [PubMed]
- Gatius, S.; Cuevas, D.; Fernández, C.; Roman-Canal, B.; Adamoli, V.; Piulats, J.M.; Eritja, N.; Martin-Satue, M.; Moreno-Bueno, G.; Matias-Guiu, X. Tumor Heterogeneity in Endometrial Carcinoma: Practical Consequences. Pathobiology 2018, 85, 35–40. [Google Scholar] [CrossRef]
- Silva, C.; Pires-Luís, A.S.; Rocha, E.; Bartosch, C.; Lopes, J.M. Phenotypic Intratumoral Heterogeneity of Endometrial Carcinomas. Int. J. Gynecol. Pathol. 2018, 37, 154–166. [Google Scholar] [CrossRef] [PubMed]
- Hutt, S.; Tailor, A.; Ellis, P.; Michael, A.; Butler-Manuel, S.; Chatterjee, J. The role of biomarkers in endometrial cancer and hyperplasia: A literature review. Acta Oncol. 2019, 58, 342–352. [Google Scholar] [CrossRef] [Green Version]
- Hendrickson, M.R.; Kempson, R.L. Ciliated carcinoma--a variant of endometrial adenocarcinoma: A report of 10 cases. Int. J. Gynecol. Pathol. 1983, 2, 1–12. [Google Scholar] [CrossRef]
- Chiu, D.K.; Tse, A.P.; Xu, I.M.; Di Cui, J.; Lai, R.K.; Li, L.L.; Koh, H.Y.; Tsang, F.H.; Wei, L.L.; Wong, C.M.; et al. Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma. Nat. Commun. 2017, 8, 517. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Braganhol, E.; Morrone, F.B.; Bernardi, A.; Huppes, D.; Meurer, L.; Edelweiss, M.I.; Lenz, G.; Wink, M.R.; Robson, S.C.; Battastini, A.M. Selective NTPDase2 expression modulates in vivo rat glioma growth. Cancer Sci. 2009, 100, 1434–1442. [Google Scholar] [CrossRef]
- Braganhol, E.; Zanin, R.F.; Bernardi, A.; Bergamin, L.S.; Cappellari, A.R.; Campesato, L.F.; Morrone, F.B.; Campos, M.M.; Calixto, J.B.; Edelweiss, M.I.; et al. Overexpression of NTPDase2 in gliomas promotes systemic inflammation and pulmonary injury. Purinergic Signal. 2012, 8, 235–243. [Google Scholar] [CrossRef] [Green Version]
- Tanos, V.; Balami, S.; Lingwood, L. Junctional zone endometrium alterations in gynecological and obstetrical disorders and impact on diagnosis, prognosis and treatment. Curr. Opin. Obstet. Gynecol. 2019, 31, 418–427. [Google Scholar] [CrossRef]
- Huang, M.; Li, X.; Guo, P.; Yu, Z.; Xu, Y.; Wei, Z. The abnormal expression of oxytocin receptors in the uterine junctional zone in women with endometriosis. Reprod. Biol. Endocrinol. 2017, 15, 1. [Google Scholar] [CrossRef] [Green Version]
- Rasmussen, C.K.; Hansen, E.S.; Dueholm, M. Two- and three-dimensional ultrasonographic features related to histopathology of the uterine endometrial-myometrial junctional zone. Acta Obstet. Gynecol. Scand. 2019, 98, 205–214. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wald, O.; Izhar, U.; Amir, G.; Kirshberg, S.; Shlomai, Z.; Zamir, G.; Peled, A.; Shapira, O.M. Interaction between neoplastic cells and cancer-associated fibroblasts through the CXCL12/CXCR4 axis: Role in non-small cell lung cancer tumor proliferation. J. Thorac. Cardiovasc. Surg. 2011, 141, 1503–1512. [Google Scholar] [CrossRef] [Green Version]
- Lis, R.; Touboul, C.; Halabi, N.M.; Madduri, A.S.; Querleu, D.; Mezey, J.; Malek, J.A.; Suhre, K.; Rafii, A. Mesenchymal cell interaction with ovarian cancer cells induces a background dependent pro-metastatic transcriptomic profile. J. Transl. Med. 2014, 12, 59. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Giatromanolaki, A.; Koukourakis, M.I.; Koutsopoulos, A.; Mendrinos, S.; Sivridis, E. The metabolic interactions between tumor cells and tumor-associated stroma (TAS) in prostatic cancer. Cancer Biol. Ther. 2012, 13, 1284–1289. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kitadai, Y. Cancer-stromal cell interaction and tumor angiogenesis in gastric cancer. Cancer Microenviron. 2010, 3, 109–116. [Google Scholar] [CrossRef] [Green Version]
- Akatsu, Y.; Takahashi, N.; Yoshimatsu, Y.; Kimuro, S.; Muramatsu, T.; Katsura, A.; Maishi, N.; Suzuki, H.I.; Inazawa, J.; Hida, K.; et al. Fibroblast growth factor signals regulate transforming growth factor-β-induced endothelial-to-myofibroblast transition of tumor endothelial cells via Elk1. Mol. Oncol. 2019, 13, 1706–1724. [Google Scholar] [CrossRef] [Green Version]
- Jhandier, M.N.; Kruglov, E.A.; Lavoie, E.G.; Sévigny, J.; Dranoff, J.A. Portal fibroblasts regulate the proliferation of bile duct epithelia via expression of NTPDase2. J. Biol. Chem. 2005, 280, 22986–22992. [Google Scholar] [CrossRef] [Green Version]
- Yu, J.; Lavoie, E.G.; Sheung, N.; Tremblay, J.J.; Sévigny, J.; Dranoff, J.A. IL-6 downregulates transcription of NTPDase2 via specific promoter elements. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 294, G748–G756. [Google Scholar] [CrossRef] [Green Version]
- Kruglov, E.A.; Nathanson, R.A.; Nguyen, T.; Dranoff, J.A. Secretion of MCP-1/CCL2 by bile duct epithelia induces myofibroblastic transdifferentiation of portal fibroblasts. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290, G765–G771. [Google Scholar] [CrossRef] [Green Version]
- Otranto, M.; Sarrazy, V.; Bonté, F.; Hinz, B.; Gabbiani, G.; Desmoulière, A. The role of the myofibroblast in tumor stroma remodeling. Cell Adh. Migr. 2012, 6, 203–219. [Google Scholar] [CrossRef] [Green Version]
- De Wever, O.; Mareel, M. Role of myofibroblasts at the invasion front. Biol. Chem. 2002, 383, 55–67. [Google Scholar] [CrossRef] [PubMed]
- Kawashiri, S.; Tanaka, A.; Noguchi, N.; Hase, T.; Nakaya, H.; Ohara, T.; Kato, K.; Yamamoto, E. Significance of stromal desmoplasia and myofibroblast appearance at the invasive front in squamous cell carcinoma of the oral cavity. Head Neck 2009, 31, 1346–1353. [Google Scholar] [CrossRef] [PubMed]
- Orimo, A.; Tomioka, Y.; Shimizu, Y.; Sato, M.; Oigawa, S.; Kamata, K.; Nogi, Y.; Inoue, S.; Takahashi, M.; Hata, T.; et al. Cancer-associated myofibroblasts possess various factors to promote endometrial tumor progression. Clin. Cancer Res. 2001, 7, 3097–3105. [Google Scholar]
- Alpízar-Alpízar, W.; Laerum, O.D.; Christensen, I.J.; Ovrebo, K.; Skarstein, A.; Høyer-Hansen, G.; Ploug, M.; Illemann, M. Tissue Inhibitor of Metalloproteinase-1 Is Confined to Tumor-Associated Myofibroblasts and Is Increased With Progression in Gastric Adenocarcinoma. J. Histochem. Cytochem. 2016, 64, 483–494. [Google Scholar] [CrossRef] [Green Version]
- Augsten, M. Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment. Front. Oncol. 2014, 4, 62. [Google Scholar] [CrossRef]
- Teng, F.; Tian, W.Y.; Wang, Y.M.; Zhang, Y.F.; Guo, F.; Zhao, J.; Gao, C.; Xue, F.X. Cancer-associated fibroblasts promote the progression of endometrial cancer via the SDF-1/CXCR4 axis. J. Hematol. Oncol. 2016, 9, 8. [Google Scholar] [CrossRef] [Green Version]
- Subramaniam, K.S.; Tham, S.T.; Mohamed, Z.; Woo, Y.L.; Mat Adenan, N.A.; Chung, I. Cancer-associated fibroblasts promote proliferation of endometrial cancer cells. PLoS ONE 2013, 8, e68923. [Google Scholar] [CrossRef]
- Ali, A.; Black, D.; Soslow, R.A. Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma. Int. J. Gynecol. Pathol. 2007, 26, 115–123. [Google Scholar] [CrossRef] [PubMed]
- Hernandez, E.; Woodruff, J.D. Endometrial adenocarcinoma arising in adenomyosis. Am. J. Obstet. Gynecol. 1980, 138, 827–832. [Google Scholar] [CrossRef]
- McCluggage, W.G. Pathologic Staging of Endometrial Carcinomas: Selected Areas of Difficulty. Adv. Anat. Pathol. 2018, 25, 71–84. [Google Scholar] [CrossRef]
- Toki, T.; Shimizu, M.; Takagi, Y.; Ashida, T.; Konishi, I. CD10 is a marker for normal and neoplastic endometrial stromal cells. Int. J. Gynecol. Pathol. 2002, 21, 41–47. [Google Scholar] [CrossRef] [PubMed]
- Srodon, M.; Klein, W.M.; Kurman, R.J. CD10 imunostaining does not distinguish endometrial carcinoma invading myometrium from carcinoma involving adenomyosis. Am. J. Surg. Pathol. 2003, 27, 786–789. [Google Scholar] [CrossRef] [PubMed]
- Nascimento, A.F.; Hirsch, M.S.; Cviko, A.; Quade, B.J.; Nucci, M.R. The role of CD10 staining in distinguishing invasive endometrial adenocarcinoma from adenocarcinoma involving adenomyosis. Mod. Pathol. 2003, 16, 22–27. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Busca, A.; Djordjevic, B.; Giassi, A.; Parra-Herran, C. IFITM1 Is Superior to CD10 as a Marker of Endometrial Stroma in the Evaluation of Myometrial Invasion by Endometrioid Adenocarcinoma. Am. J. Clin. Pathol. 2016, 145, 486–496. [Google Scholar] [CrossRef] [PubMed] [Green Version]
EC Histologic Types | Number of Total Cases (n) | Cases without Myometrial Infiltration | Cases with Myometrial Infiltration | Adenomyotic Lesions | ||
---|---|---|---|---|---|---|
with Desmoplastic Reaction | without Desmoplastic Reaction | |||||
Endometrioid carcinoma | Grade 1 | 20 * | 5 | 12 * | 3 | 4 |
Grade 2 | 10 | 1 | 8 | 1 | 0 | |
Grade 3 | 17 | 2 | 14 | 1 | 2 | |
Serous carcinoma | 5 * | 0 | 5 * | 0 | 1 | |
Carcinosarcoma | 3 | 1 | 2 | 0 | 1 | |
Mixed carcinoma | 2 | 0 | 2 | 0 | 0 | |
Total | 57 | 9 | 43 | 5 | 8 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Rodríguez-Martínez, A.; Trapero, C.; Vidal, A.; Piulats, J.M.; Gómez de Aranda, I.; Sévigny, J.; Fernández-Montolí, M.E.; Ponce, J.; Matias-Guiu, X.; Martín-Satué, M. Characterization of the Endometrial MSC Marker Ectonucleoside Triphosphate Diphosphohydrolase-2 (NTPDase2/CD39L1) in Low- and High-Grade Endometrial Carcinomas: Loss of Stromal Expression in the Invasive Phenotypes. J. Pers. Med. 2021, 11, 331. https://doi.org/10.3390/jpm11050331
Rodríguez-Martínez A, Trapero C, Vidal A, Piulats JM, Gómez de Aranda I, Sévigny J, Fernández-Montolí ME, Ponce J, Matias-Guiu X, Martín-Satué M. Characterization of the Endometrial MSC Marker Ectonucleoside Triphosphate Diphosphohydrolase-2 (NTPDase2/CD39L1) in Low- and High-Grade Endometrial Carcinomas: Loss of Stromal Expression in the Invasive Phenotypes. Journal of Personalized Medicine. 2021; 11(5):331. https://doi.org/10.3390/jpm11050331
Chicago/Turabian StyleRodríguez-Martínez, Aitor, Carla Trapero, August Vidal, Josep Maria Piulats, Inmaculada Gómez de Aranda, Jean Sévigny, Maria Eulàlia Fernández-Montolí, Jordi Ponce, Xavier Matias-Guiu, and Mireia Martín-Satué. 2021. "Characterization of the Endometrial MSC Marker Ectonucleoside Triphosphate Diphosphohydrolase-2 (NTPDase2/CD39L1) in Low- and High-Grade Endometrial Carcinomas: Loss of Stromal Expression in the Invasive Phenotypes" Journal of Personalized Medicine 11, no. 5: 331. https://doi.org/10.3390/jpm11050331